Migraine Disorders Clinical Trial
— Migraine AlertOfficial title:
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
NCT number | NCT02910921 |
Other study ID # | 16-005803 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 2016 |
Est. completion date | July 31, 2018 |
Verified date | August 2018 |
Source | Second Opinion Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch,
simon@somobilehealth.com 408-981-3814) and Allergan. Mayo Clinic investigators are conducting
the clinical trial, Second Opinion Health is providing the software for use in the trial
(Migraine Alert app for data collection, analysis and machine learning algorithms), and
Allergan is providing funding.
The investigators hypothesize that the use of a mobile phone app and Fitbit wearable to
collect daily headache diary data, exposure/trigger data and physiologic data will predict
the occurrence of migraine attacks with high accuracy. The objective of the trial is to
assess the ability to use daily exposure/trigger and symptom data, as well as physiologic
data (collected by Fitbit) to create individual predictive migraine models to accurately
predict migraine attacks in individual patients via a mobile phone app.
Status | Completed |
Enrollment | 19 |
Est. completion date | July 31, 2018 |
Est. primary completion date | July 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects fulfilling ICHD-3beta criteria for migraine with average of 5 - 10 migraine attacks per month and up to 12 headache days per month - Males of females 18 years of age or older - Subject report of weather being one of the triggers - Subject has an iPhone - Subject is willing to wear a Fitbit device for the duration of the study - Subject has an active Facebook account or is willing to create one Exclusion Criteria: - Children younger than 18 years of age - Subjects with headaches other than migraine or probable migraine - Inability to provide informed consent - Not willing to maintain a daily diary - Current participation in another clinical trial |
Country | Name | City | State |
---|---|---|---|
United States | University of Southern California | Los Angeles | California |
United States | Mayo Clinic Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
Second Opinion Health | Allergan, Mayo Clinic, University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC of individual prediction models using cross validation data on environmental and physiological variables. | The study will develop a separate predictive model for each participant that will forecast probability of experiencing a migraine attack during a particular interval. The outcome measures performance of this model using the Area Under the Curve (AUC) metric. AUC measures how often the algorithm predicts a higher probability for a migraine over non-migraine. This measure is attractive because it is independent of the quantization threshold, which is required for other metrices such as precision/recall. In the baseline phase, 30% of the data will be randomly selected for cross validation and will not used for training the model. Once the model is trained, the AUC of the model is measured on the cross validation data as the outcome of this phase. The data will include various measurements of weather such as temperature, pressure, humidity, wind and physiological measurements such as sleep duration and quality and activity level measured through a wearable Fitbit device. | 10 weeks | |
Primary | AUC of individual prediction models using post prediction data on environmental and physiological variables. | The metric and the type of the data is the same as in Outcome 1. The only difference is that the data is obtained from the user after the model is trained. The user is not shown the prediction to avoid expectancy bias. | 10 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432379 -
BOTOX® Prophylaxis in Patients With Chronic Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05048914 -
Migraine Abortive Treatment
|
||
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT02766517 -
Biomarker Study in Participants With Migraine
|
Early Phase 1 | |
Completed |
NCT00963937 -
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
|
Phase 3 | |
Not yet recruiting |
NCT03632928 -
Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
|
||
Completed |
NCT02559895 -
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
|
Phase 3 | |
Completed |
NCT01435941 -
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
|
N/A | |
Completed |
NCT00743015 -
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
|
Phase 1 | |
Completed |
NCT01376141 -
Drug Use Investigation for IMIGRAN Tablet
|
N/A | |
Completed |
NCT02183688 -
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
|
Phase 3 | |
Completed |
NCT06061588 -
"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"
|
N/A | |
Completed |
NCT03588364 -
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
|
N/A | |
Completed |
NCT04091321 -
Association Between Chronic Headache and Back Pain With Childbirth
|
||
Completed |
NCT00385008 -
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
|
Phase 3 | |
Active, not recruiting |
NCT05888298 -
Proximal and Distal Approach GON RFT in Migraine
|
N/A | |
Completed |
NCT03435185 -
Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT02565186 -
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
|
Phase 3 |